Statistics from Altmetric.com
We read with interest the article by Arevalo et al1 about the development of a tractional retinal detachment (TRD) following the use of intravitreal bevacizumab (Avastin; Genetech Inc., San Francisco, California, USA) as an adjuvant to vitrectomy for the management of severe proliferative diabetic retinopathy (PDR). They warned that TRD might occur or progress shortly after intravitreal bevacizumab. We present a case of a retinal detachment with macular hole (MH–RD) that developed after intravitreal bevacizumab that was used for neovascular glaucoma as a result of severe PDR.
A 40-year-old man with diabetes of 19 years presented with PDR and neovascular glaucoma in the right eye that was refractory to panretinal photocoagulation (PRP). He was being treated with insulin but had …